Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
Waters Corp (NYSE: WAT) reported Q2 2026 revenue of $1.645B, above guidance, with $828M organic revenue (+7% reported, +9% constant currency) and $817M from acquired Biosciences and Diagnostic Solutions. Adjusted EPS was $3.05 (high end of guidance); GAAP EPS was -$1.39. Waters raised full-year 2026 guidance: organic constant-currency growth 7% to 9% and adjusted EPS $14.45 to $14.65.
How this was made
The 30-second read
Why it matters
The key actionable item is the company raising every component of full-year 2026 guidance, with adjusted EPS increased to $14.45-$14.65 and organic constant-currency revenue growth raised to 7%-9%.
Market read
A guidance raise after Q2 outperformance typically drives near-term estimate revisions and can re-rate the stock if investors were positioned for weaker demand or slower integration.
What to watch
The guidance raise is tied to end-market strengthening and integration momentum; traders should monitor whether FX translation and acquisition-related costs could reintroduce volatility in subsequent quarters.
Background
Waters reported Q2 2026 results across its Analytical Sciences Division and Biosciences and Diagnostic Solutions businesses, including commentary on an integration and growth revitalization plan.
Ticker impact
Waters reported Q2 2026 revenue of $1.645B and raised full-year 2026 guidance, including adjusted EPS to $14.45-$14.65.
Likely positive near-term bias as raised EPS and revenue ranges can support upward estimate revisions, though FX and acquisition accounting remain watch items.
The article discloses specific Q2 results (revenue, adjusted EPS) and a full-year guidance raise across organic growth, acquired revenue, and adjusted EPS, which are direct drivers for earnings expectations.
Market effects
Signals improving end-market recovery for life-science tools, potentially supportive for peers exposed to analytical sciences and diagnostics demand.
Limited direct regional read-through; primarily a US-listed large-cap life-science instruments signal.
Moderate global relevance via constant-currency organic growth and FX translation commentary, relevant to multinational tool demand.
Counterpoint
GAAP EPS remains deeply negative due to acquisition-related purchase accounting charges, so the quality of earnings and cash generation may still be questioned by skeptics.
Key entities
- companyWaters Corporation
Reported Q2 2026 financial results and raised full-year 2026 guidance, including adjusted EPS and organic revenue growth.
- executiveUdit Batra
CEO who attributed outperformance to broad-based growth, integration momentum, and strengthening end-market conditions.
